I'm at Spike Pharmaceuticals
Release time:
2023-04-21
My years in Ye Ke
, the production department of Jianfeng Pharmaceutical
■, passed quietly. I have joined Jianfeng Pharmaceutical for three years.
My fate with Peak can probably be counted from when I graduated in 2019 and looked for an internship unit. At that time, the school recommended us to choose two-way internship units among many pharmaceutical companies in Jinhua. I made and delivered many resumes. The first thing I received was the interview notice from Jianfeng Pharmaceutical. The interview was conducted on a sunny afternoon. Many leaders of Jianfeng Pharmaceutical Co., Ltd. were present. I was deeply shocked by the importance they attached to interns. Fortunately, my performance has been recognized by the leaders, and Jianfeng Pharmaceutical has become my intended internship unit.
I didn't expect a good thing to happen, faster than the induction internship and more suddenly the new crown epidemic. With the outbreak of the epidemic in early 2020, schools delayed internship arrangements for safety reasons, and many businesses, either directly declared closure or canceled internships to reduce mobility and save money because of the severe impact of the epidemic. Later, the epidemic was alleviated to a certain extent, although the resumption of work and economic recovery was regarded as the top priority of the whole society, but according to the original plan to arrange new internships in very few enterprises. Luckily for me, Spike did.
factory car pick-up 2.1 line, free access to epidemic prevention supplies... Internship life, although somewhat monotonous, but so that the envious of the students around. Bathed in a harmonious working atmosphere, feeling the meticulous care of the leaders and the friendship and mutual assistance among colleagues, when I graduated, I did not hesitate and chose to join the peak family.
After I really took up my job, I participated in the installation, commissioning and confirmation of the equipment in the newly-built factory area, independently operated the coating equipment worth millions of dollars, assumed greater job responsibilities, and experienced different work pressures. I also felt confused and lost for a while. Whenever I feel afraid of difficulties, my mind can always see the grand blueprint drawn by the company, imagining the glory and dream of the preparation products I have participated in to go abroad and go to the world, and I am full of vitality in an instant. I swear, I must turn this goal into a beautiful reality.
Peak Pharmaceutical is my first job. In three years, I have completed the transformation from a student to a workplace person, becoming an "old man" and a job master in the workshop. In this process of growing up, I also have some of my own insights and experiences. For example, I should deal with the things and things around me with a professional attitude and not mix my personal emotions with them. Don't be discouraged at any time, but keep high morale. No one is born to do things. Only by continuous learning can we do better and better, and so on. In the future work, I will be in the spirit of ownership, starting from doing a good job in daily work, starting from me, starting from now on, and persevering in my own work to do my best to transform first-class working conditions into first-class economic benefits. I want to work with my lovely colleagues, roll up my sleeves and work hard for a hundred years of peak, and strive for a better self at the peak.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page